Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 1/20 | 0.45 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 12/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.37 |
| ▸ | GIPR | P48546 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3419410 | 0.91 | AR (0.44) | UBE2MDCUN1D1ARPGRRXRA | |
| SCHEMBL3410635 | 0.85 | UBE2M (0.44) | UBE2MDCUN1D1ARPGRRXRA | |
| SCHEMBL19745673 | 0.83 | RXRA (0.50) | UBE2MDCUN1D1ARPGRRXRA | |
| SCHEMBL3288362 | 0.82 | AR (0.42) | UBE2MDCUN1D1ARPGR | |
| SCHEMBL3412152 | 0.82 | AR (0.43) | ARPGRRXRARXRBRXRG | |
| SCHEMBL3415456 | 0.81 | S1PR1 (0.45) | UBE2MDCUN1D1ARPGRTAS2R14 | |
| SCHEMBL3417378 | 0.81 | S1PR1 (0.45) | UBE2MDCUN1D1ARPGRTAS2R14 | |
| SCHEMBL3418822 | 0.79 | AR (0.46) | ARPGR | |
| SCHEMBL3417367 | 0.78 | AR (0.42) | UBE2MDCUN1D1ARPGRRXRA | |
| SCHEMBL19745814 | 0.78 | AR (0.45) | UBE2MDCUN1D1ARPGRRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834063-B2 | 4-[(Cyclopropylmethyl)(2-{[4-(1,1-dimethylethyl)phenyl]oxy}ethyl)amino]-2-(trifluoromethyl)benzonitrile; modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors; osteoporosis, muscle wasting,endometriosis, cardiovascular disease; breast, uterine cancer, prostatic hyperplasia | GLAXOSMITHKLINE LLC (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080255124-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255124-A1 | Chemical Compounds | NR3C2, NR5A1, NR3C1 | UBE2M 1217/4885DCUN1D1 3532/4885AR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.